Rexmyelocel T - Rexgenero

Drug Profile

Rexmyelocel T - Rexgenero

Alternative Names: BM-MNCs - Rexgenero; Bone-marrow-derived-mononuclear-cells-Rexgenero; REX-001

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rexgenero
  • Class Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell replacements; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Peripheral ischaemia

Most Recent Events

  • 30 Jan 2018 Rexmyelocel T receives Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data
  • 21 Dec 2017 Phase-III clinical trials in Peripheral ischaemia in Portugal (Intra-arterial) (EudraCT2016-000240-34) (EudraCT2016-003980-21)
  • 15 Sep 2017 Phase-III clinical trials in Peripheral ischaemia in Poland (Intra-arterial) (EudraCT2016-000240-34) (EudraCT2016-003980-21)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top